NRIX vs TENX
NRIX: Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate bexobrutideg in CLL and partnerships spanning Roche, Gilead, and Sanofi. TENX: Tenax Therapeutics is a clinical-stage biotechnology company developing specialized therapies for pulmonary hypertension and other cardiopulmonary conditions.
Side-by-side fundamentals
| Metric | NRIX | TENX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $23.21 | $16.19 | |
| Market cap as of 2026-08-03 | $2.4B | $429M | |
| PEG as of 2026-08-03 | -0.21 | n/a | |
| Net margin as of 2026-08-03 | -928.4% | -10115.8% | NRIX higher |
| Gross margin as of 2026-08-03 | n/a | +100.0% | |
| Operating margin as of 2026-08-03 | -982.4% | -10390.5% | NRIX higher |
| ROE as of 2026-08-03 | -76.1% | -56.3% | TENX higher |
| ROA as of 2026-08-03 | -57.3% | -53.1% | TENX higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-03 | -58.4% | -82.9% | NRIX higher |
| Revenue CAGR (3y) SEC XBRL | +29.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-03 | 1.37 | 0.96 | |
| 1-year return as of 2026-07-31 close | +106.1% | +167.6% | TENX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.